Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metagenomi (MGX) Current Deferred Revenue (2023 - 2025)

Metagenomi (MGX) has disclosed Current Deferred Revenue for 3 consecutive years, with $8.7 million as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue fell 61.78% to $8.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.7 million through Dec 2025, down 61.78% year-over-year, with the annual reading at $8.7 million for FY2025, 61.78% down from the prior year.
  • Current Deferred Revenue for Q4 2025 was $8.7 million at Metagenomi, down from $12.9 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $48.3 million in Q1 2024, with the low at $8.7 million in Q4 2025.
  • Average Current Deferred Revenue over 3 years is $27.5 million, with a median of $25.5 million recorded in 2025.
  • Peak annual rise in Current Deferred Revenue hit 42.56% in 2025, while the deepest fall reached 61.78% in 2025.
  • Over 3 years, Current Deferred Revenue stood at $48.1 million in 2023, then plummeted by 52.65% to $22.8 million in 2024, then crashed by 61.78% to $8.7 million in 2025.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $8.7 million, $12.9 million, and $18.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.